Global biotechnology company NodThera is developing a new class of potent and selective small-molecule NLRP3 inhibitors for the treatment of diseases driven by chronic inflammation, such as ...
BACKPACKOriginal ArticleTitle:Dual-function natural products: Farnesoid X receptor agonist/inflammation inhibitor for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback